<DOC>
	<DOCNO>NCT00744939</DOCNO>
	<brief_summary>Assess potential risk NSF subject renal impairment ( moderate ) post magnevist injection . Subjects screen within 48 hour previously schedule MRI , meet enrollment criterion enrol prior MRI follow 2 year post MRI visit occur 1yr 2 yr timepoints , addition follow-up phone call conduct 1 , 3 , 6 18 month assess skin change suggestive NSF .</brief_summary>
	<brief_title>Risk Nephrogenic Systemic Fibrosis ( NSF ) Patients With Moderate Renal Insufficiency After Administration Magnevist</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Nephrogenic Fibrosing Dermopathy</mesh_term>
	<criteria>Patients must moderate ( eGFR 3059 ml/min/1.73 m^2 ) renal impairment schedule contrast enhance MRI Magnevist Injection recommend dose 0.1 mmol/kg . Gadolinium Based Contrast Agent ( Magnevist ) enhance MRI within 12 month prior administration Magnevist History NSF Clinically unstable age &lt; 2 yr</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Gadolinium</keyword>
	<keyword>NSF</keyword>
	<keyword>Renal Impairment</keyword>
	<keyword>chemically induced</keyword>
	<keyword>adverse effect</keyword>
	<keyword>Contrast Media</keyword>
	<keyword>complication</keyword>
</DOC>